MyOme makes whole-genome analysis available worldwide on Oracle Cloud

Why it matters

Oracle gives MyOme computing infrastructure and a potential route to healthcare organizations through its ecosystem and Marketplace. The harder proof remains clinical: whether genetic risk estimates change care and improve outcomes.

MyOme said on September 24th that its whole-genome analysis platform and testing services are available worldwide on Oracle Cloud Infrastructure, adding Oracle PartnerNetwork membership and a route through Oracle's Marketplace to its push for broader healthcare distribution. The announcement puts infrastructure and access behind a thesis that has followed co-founder and executive chairman Matt Rabinowitz across multiple companies: genetic information should help clinicians act before disease develops. MyOme's announcement describes the Oracle collaboration as a way to bring that approach to more healthcare organizations through Oracle's ecosystem and Marketplace.

Rabinowitz came to genetic testing through a family loss. Stanford's account says a child in his family died from a genetic disease in 2003, an experience that pushed him to build tools aimed at giving families earlier genetic answers. He later co-founded Natera, the diagnostics company, and MyOme brings him back to a related problem with a broader data premise: sequence the whole genome once, then analyze it again as a person's health and the science change.

Before genetics, Rabinowitz co-founded online merchandising company Panop.com, which Stanford says sold for $100 million, and founded Rosum, which used television signals to augment GPS. His path from signal processing and location technology to genomic testing gives MyOme's pitch a distinct engineering thread: combine large, complex datasets with models that can produce useful decisions. MyOme's company profile identifies Rabinowitz as executive chairman and co-founder, alongside co-founders Akash Kumar and Kate Im.

One genome, many clinical questions

MyOme says it sequences a person's whole genome once and analyzes millions of variants alongside clinical risk factors. Its platform combines polygenic risk scores for common conditions such as coronary artery disease, type 2 diabetes and certain cancers with findings related to single-gene conditions and medication response. MyOme's argument is that a whole-genome sample can answer more questions than a narrow gene panel and can be reanalyzed later without collecting a new genetic sample.

The Oracle deal pairs that product with cloud computing and a route to healthcare organizations. MyOme has joined Oracle PartnerNetwork (OPN), which Oracle expanded on September 22nd to include healthcare and life-sciences partner incentives. MyOme says OPN membership helps bring its capabilities to healthcare organizations through Oracle's ecosystem and Marketplace. OCI supplies computing capacity for large-scale analysis, according to the company's announcement, while Oracle's description of the expanded program details the healthcare and life-sciences incentives.

Whole-genome interpretation requires substantial computing and clinical distribution, while a service sold through health systems must fit into existing procurement and care workflows. Oracle's ecosystem and Marketplace offer MyOme a route to potential healthcare customers. That route is not evidence that clinicians have adopted the scores or that patients are receiving preventive care because of them.

MyOme has been building toward that clinical use case for years. In 2022, it announced a $23 million Series B, led by Healthcare Venture Partners, with SoftBank Corp. and Natera joining existing backers Sequoia Capital, Foresite Capital and Founders Fund. MyOme said the financing would support commercialization of its whole-genome platform and clinical reports for health systems. The Oracle announcement extends that effort from financing and product development to cloud infrastructure and distribution.

The clinical test is still the important one

A risk score can change a decision only if it is accurate for the patient in front of a clinician, improves on existing tools, and leads to an intervention that helps. MyOme's March 2026 announcement described research on the stability of integrated genetic and clinical risk predictions for coronary artery disease. The study, published in the American Journal of Preventive Cardiology, examines consistency in individual risk estimates; it does not establish that MyOme's scores improve patient outcomes. The study announcement and the published paper provide evidence on prediction, a necessary step toward routine use rather than evidence that resulting care improves health.

MyOme's product is designed to turn a one-time genome into a reusable clinical resource. Oracle can help process and distribute that resource, while compute capacity alone cannot establish whether an individual risk estimate should change a clinician's recommendation. The American Heart Association's scientific statement on cardiovascular polygenic risk scores frames implementation around efficacy, potential harms and practical logistics, including whether adding a score meaningfully improves risk assessment.

MyOme's worldwide availability claim describes the reach of the service as announced, not worldwide clinical adoption or proven benefit. MyOme's bet is that a broad genomic foundation, paired with the right clinical context, can make prevention more personalized over time. Oracle gives that bet computing infrastructure and a route through its partner ecosystem and Marketplace. Rabinowitz's harder task is to show that more genetic information leads to better decisions in everyday care.